Nature Reviews Clinical Oncology - Table of Contents alert Volume 10 Issue 10

Advertisement
New technology for the proteomic age. A leader in protein-based diagnostic tests. Biodesix is improving the precision of personalized medicine by advancing beyond the exploration of genes. Biodesix is a molecular diagnostics company providing physicians with diagnostic tests for earlier disease detection, diagnosis, disease monitoring and better therapeutic guidance.
TABLE OF CONTENTS
October 2013 Volume 10 Number 10		Advertisement
Impact Factor 15.031 *	In this issue Research Highlights News and Views Reviews Perspectives Also this month  Web collection: Hepatocellular carcinoma	New model systems to advance understanding of serous epithelial ovarian cancer Topic Editors: Elise Kohn and Viive M. Howell ¦ Submission deadline: 30 Sep 2013 This Research Topic from Frontiers in Oncology will showcase new model systems for SEOC research including normal, cancerous and cancer-associated cell lines and their use in 2D, 3D and co-culture systems as well as in vivo approaches that utilize the latest advances in transgenics and imaging.  Find out more about contributing to this RT
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Web Collection on Hepatocellular carcinoma from Nature Reviews Clinical Oncology and Nature Reviews Gastroenterology & Hepatology This web collection includes a selection of articles covering key aspects of the pathogenesis and treatment of HCC, including insights into disease pathways and possible future therapeutic targets.  FREE for a limited time!  This Collection is produced with educational support from  Onyx Pharmaceuticals, Inc. and Bayer Healthcare LLC
RESEARCH HIGHLIGHTS Top Genetics: Signatures of mutational processes in cancer—a big step closer Published online: 03 September 2013 p545 | doi:10.1038/nrclinonc.2013.162 PDF Targeted therapies: HERA update—1 year is standard Published online: 06 August 2013 p546 | doi:10.1038/nrclinonc.2013.145 PDF Breast cancer: Mutations in breast cancer stem cells correlate with metastases Published online: 13 August 2013 p546 | doi:10.1038/nrclinonc.2013.146 PDF Palliative care: Steroids to combat fatigue Published online: 13 August 2013 p546 | doi:10.1038/nrclinonc.2013.147 PDF Genetics: Glioblastoma landscape revealed Published online: 20 August 2013 p547 | doi:10.1038/nrclinonc.2013.157 PDF Targeted therapies: Hope for antiangiogenic therapy in advanced gastric cancer Published online: 20 August 2013 p548 | doi:10.1038/nrclinonc.2013.156 PDF Breast cancer: BEATRICE bevacizumab trial—every cloud has a silver lining Published online: 27 August 2013 p548 | doi:10.1038/nrclinonc.2013.161 PDF IN BRIEF Haematological cancer: Induction with bortezomib improves response in myeloma | Lung cancer: High-volume centres associated with best outcomes | Basic research: Plausible mechanism for chemoradioprotection identified PDF Clinical Oncology JOBS of the week Independent International Research Position in ?Molecular and Cellular Basis for Tissue Homeostasis and Inflammation? IFOM (Foundation FIRC Institute of Molecular Oncology) Breast Cancer Post-Doctoral Research Fellow University of Colorado Denver Medical Oncology More Science jobs from More science events from
NEWS AND VIEWS		Top
Lung cancer: Maintenance therapy and precision medicine in NSCLC Rafael Rosell & Niki Karachaliou Published online: 20 August 2013 p549 | doi:10.1038/nrclinonc.2013.152 Two phase III trials have shown that prolonging chemotherapy duration improves outcome in patients with nonsquamous non-small-cell lung cancer. Pemetrexed versus placebo, and pemetrexed-bevacizumab versus bevacizumab was tested in patients without disease progression after pemetrexed-cisplatin treatment. Biomarker-directed chemotherapy and/or targeted therapy could further improve treatment outcomes for patients with lung cancer. Full Text | PDF
Targeted therapies: Afatinib—new therapy option for EGFR-mutant lung cancer Helena A. Yu & William Pao Published online: 20 August 2013 p551 | doi:10.1038/nrclinonc.2013.154 On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients. Full Text | PDF
Innovation: Tumour board—introducing real time to oncology management Timothy Craig Allen & Bryan A. Liang Published online: 27 August 2013 p552 | doi:10.1038/nrclinonc.2013.159 The tumour board has outlived its intended function—it delays care, provides minimal patient benefit, is costly, does not account for patient psychosocial issues, is not evidence-based and has numerous potential legal issues. Instead, multidisciplinary oncology teams using real-time social media and networking that integrates patient input is a better approach. Full Text | PDF
Haematological cancer: Treatment of smoldering multiple myeloma S. Vincent Rajkumar & Robert A. Kyle Published online: 03 September 2013 p554 | doi:10.1038/nrclinonc.2013.160 In a recent randomized trial, lenalidomide plus low-dose dexamethasone prolonged overall survival in patients with high-risk smoldering multiple myeloma. Although the results are impressive, the generalizability is limited to a small subset of patients. Additional studies are needed to identify specific patient populations who can benefit from early intervention. Full Text | PDF
REVIEWS		Top
Molecular targets on the horizon for kidney and urothelial cancer Joaquim Bellmunt, Bin T. Teh, Giampaolo Tortora & Jonathan E. Rosenberg Published online: 27 August 2013 p557 | doi:10.1038/nrclinonc.2013.155 Advances in the arena of whole-genome sequencing have revealed biomarkers of drug sensitivity and resistance in both renal cell carcinoma and urothelial tumours. This Review article highlights those markers of particular interest and discusses the preclinical and clinical evidence supporting their utility. Abstract | Full Text | PDF
Drug rechallenge and treatment beyond progression—implications for drug resistance Elizabeth A. Kuczynski, Daniel J. Sargent, Axel Grothey & Robert S. Kerbel Published online: 03 September 2013 p571 | doi:10.1038/nrclinonc.2013.158 There are many circumstances where patients respond to reintroduction of the same therapy (drug rechallenge) following relapse or disease progression during therapy, and in a few cases, when a therapy is continued beyond disease progression. The authors comprehensively describe the available data on rechallenge and continuation beyond progression treatment strategies, discuss the potential mechanisms explaining tumour re-sensitization with reintroduced or continued therapy, and make the case for why drug resistance definitions need to be re-evaluated. Abstract | Full Text | PDF | Supplementary information
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma HowardHoward L. Kaufman, John M. Kirkwood, F. Stephen Hodi, Sanjiv Agarwala, Thomas Amatruda, Steven D. Bines, Joseph I. Clark, Brendan Curti, Marc S. Ernstoff, Thomas Gajewski, Rene Gonzalez, Laura Jane Hyde, David Lawson, Michael Lotze, Jose Lutzky, Kim Margolin, David F. McDermott, Donald Morton, Anna Pavlick, Jon M. Richards, William Sharfman, Vernon K. Sondak, Jeffrey Sosman, Susan Steel, Ahmad Tarhini, John A. Thompson, Jill Titze, Walter Urba, Richard White & Michael B. Atkins Published online: 27 August 2013 p588 | doi:10.1038/nrclinonc.2013.153 Immunotherapy is associated with durable clinical benefit in patients with melanoma, and this consensus statement outlines recommendations for its use. The panel has based their guidance on the available evidence and outlines a treatment paradigm using drugs that are FDA approved. Abstract | Full Text | PDF | Supplementary information
PERSPECTIVES		Top
SCIENCE AND SOCIETY Clinical trials to improve childhood cancer care and survival in sub-Saharan Africa Trijn Israëls, Joyce Kambugu, Francine Kouya, Nader Kim El-Mallawany, Peter B. Hesseling, Gertjan J. L. Kaspers, Tim Eden, Lorna Renner & Elizabeth M. Molyneux Published online: 30 July 2013 p599 | doi:10.1038/nrclinonc.2013.137 In this Science & Society article, the authors provide their personal experience of treating children in low and middle-income countries in sub-Saharan Africa. The authors discuss how conducting clinical trials in this environment can be used for the benefit of all paediatric patients, and outline the measures that need to be put in place to ensure that the outcomes in improved care are met. Abstract | Full Text | PDF
Advertisement
Nature Insight Tumour Heterogeneity Tumour heterogeneity has important clinical implications, as it can explain therapeutic resistance, but also point to novel strategies to effectively treat cancers in a more personalised manner.  Access the Insight free online for three months
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2012. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.